ArticleAsian journal of andrology

Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.

Jin-Ge Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.